Call Us: 1.800.873.5297

By

The New York Times Reports on a Study Analyzing the Effect of “Free Samples” where Health is Concerned

On April 18, 2014, The New York Times reported on a study published by JAMA Dermatology, which concluded that the practice of providing free samples to physicians favorably influences the number of prescriptions written for that drug. The research further supported that it is the pharmaceutical companies who win after a comparison of cost based […]

By

FDA Announces Voluntary Recall of Thinogenics Weight Loss Capsules

On April 18, 2014 the FDA announced the recall of weight loss drug Thinogenics manufactured by Nature’s Universe. This announcement comes after the FDA’s analysis of the drug determined that the product contained the appetite suppressant sibutramine. Nature’s Universe notified the public that it is recalling all lots of Thinogenics sold internationally prior to February […]

By

Trichloroethylene Vapor Mitigation Systems Installed in Elmwood Park

Early this year, the United States Environmental Protection Agency (EPA) began installing venting systems in houses in the Elmwood Park and Chicago Heights Boulevard neighborhoods near Olivette and Overland, Missouri. These safety measures come after the EPA and the Missouri Department of Natural Resources (MDNR) detected contaminated groundwater and chemical vapors in the neighborhood. The […]

By

Abbott Recalls Defective Blood Glucose Monitoring Systems

The Food and Drug Administration (FDA) posted a press release on March 15, 2014 where Abbott Diabetes Care announced its voluntarily recall of the FreeStyle Blood Glucose Meter and the FreeStyle Flash™ Blood Glucose Meter. Abbott Diabetes Care, based in Alameda, California, announced that these two products at issue have not been produced since 2010 […]

By

Covidien Recalls Certain Aneurism Detection Devices Due to Risk of Stroke or Death

The Food and Drug Administration (FDA) posted a press release on April 11, 2014 where Covidien announced its voluntarily recall of two of its aneurism detection devices – the Pipeline™ Embolization Device and Alligator™ Retrieval Device. Covidien provided that it learned of the defect through internal product testing and has not received any injury reports […]

By

Testosterone Drugs Under Review by Food and Drug Administration (FDA) and European Medicines Agency (EMA)

The FDA previously announced on January 31, 2014 that it would investigate a potential link between testosterone use and stroke, myocardial infarction (MI), and death in light of the findings of certain studies. Now Bloomberg reports that the European Medicines Agency, the regulatory authority in the European Union, has also announced that it will review […]

By

TVM Lawsuit Update: 1.2 Million Verdict Against Johnson & Johnson’s Ethicon® Transvaginal Mesh

Bloomberg reports that a Texas jury has rendered a verdict in favor of a woman who alleged one of the company’s Ethicon® transvaginal mesh products was defectively designed and caused her injuries. The jury ordered the manufacturer of the transvaginal mesh product, Johnson & Johnson, to pay $1.2 million dollars in damages. The Texas case […]

By

Actos® MDL Trial Update: Jury Awards Plaintiff $9 Billion in Punitive Damages

The first federal Actos® trial in the MDL concluded on Monday, April 7th. After deliberations, the jury awarded the plaintiff $1.5 million in compensatory damages and $9 billion in punitive damages ($6 billion against Takeda; $3 billion against Eli Lilly). The first trial in the Multidistrict Litigation In re: Actos® (Pioglitazone) Products Liability Litigation (MDL […]

By

Public Citizen Urges FDA to Add Black Box Warning to Testosterone Products due to Increased Risk of Heart Attack and Cardiovascular Dangers

An article published in the Journal of American Medical Association (JAMA) on March 26, 2014 provides that Public Citizen, a consumer advocacy group, has petitioned the FDA to add a black box warning to the labels of testosterone products to warn about heart attack and other cardiovascular risks. The black box warning is the strongest […]

By

GlaxoSmithKline Recalls Weight Loss Drug Alli® due to Possible Product Tampering

CNN reports that the British company GlaxoSmithKline has recalled Alli®, an over-the-counter weight loss drug, due to possible product tampering. The company said that “a range of tablets and capsules of various shapes and colors were reported to be found inside bottles [and] [a]dditionally, some bottles inside the outer carton were missing labels and had […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.